Human Anti-Denosumab Antibody specificity titration ELISAEnlarge
A microtiter plate was coated overnight with denosumab, human RANKL, human IgG1/kappa, human IgG2/kappa or human IgG1/lambda at a concentration of 5 µg/ml. For complex formation, denosumab, at a concentration of 2µg/mL, was added to RANKL coated wells after blocking. After washing and blocking with PBST+5% BSA, detection was performed using Human Anti-Denosumab:HRP Antibody clone AbD26781_hIgG1 (HCA283P) titrated to the given concentrations in PBST, followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data for binding to denosumab and to the RANKL-denosumab complex is shown as the mean of three measurements.